Heartflow (HTFL) Revenue & Revenue Breakdown
Heartflow Revenue Highlights
Latest Revenue (Y)
$125.81M
Latest Revenue (Q)
$43.42M
Heartflow Revenue by Period
Heartflow Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $125.81M | 44.32% |
| 2023-12-31 | $87.17M | - |
Heartflow generated $125.81M in revenue during NA 2024, up 44.32% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Heartflow Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $43.42M | 16.72% |
| 2025-03-31 | $37.20M | 19.81% |
| 2024-06-30 | $31.05M | 15.69% |
| 2024-03-31 | $26.84M | - |
Heartflow generated $43.42M in revenue during Q2 2025, up 16.72% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Heartflow Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PRGO | Perrigo | $4.37B | $1.04B |
| SGRY | Surgery Partners | $3.11B | $821.50M |
| PRVA | Privia Health Group | $1.74B | $580.42M |
| LIVN | LivaNova | $1.25B | $357.80M |
| ATEC | Alphatec | $424.26M | - |
| ZLAB | Zai Lab | $398.99M | $116.09M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| TVTX | Travere Therapeutics | $233.18M | $164.86M |
| TARS | Tarsus Pharmaceuticals | $182.95M | $118.70M |
| HTFL | Heartflow | $125.81M | $43.42M |
| IRON | Disc Medicine | - | - |